About this trial

Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence/absence of Helicobacter pylori (H. pylori) in the stomach.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Biopsies

Treatment groups

100 Participants
are divided into 1 treatment group

Locations

1
CHU de la Guadeloupe97159, Pointe-à-PitreCHU de La Guadeloupe, Guadeloupe

Sponsors and collaborators

Centre Hospitalier Universitaire de la Guadeloupe

Lead sponsor